Rigor Reviewed

Rigor-Reviewed Manuscript

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Name: Adcurare Rigor Record — Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
Item: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
Rating: 79
Author: Adcurare

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G.

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Adcurare Rigor Review — 5★ (Exemplary), 0 critical, 9 high issues for “Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial”

Links back to this Rigor Record.

Adcurare Editorial

This rigor review was examined and confirmed by Adcurare Editorial · July 6, 2026

Adcurare Rigor Review

Rigor Reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: lowEngine: 7.6.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
No reported statistical tests were found to recompute.

No specific rigor problems surfaced by the checks that ran.

This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The manuscript reports a well-conducted phase 1 trial with a strong scientific premise and transparent reporting. However, several reporting gaps in study design (randomization method, blinding details, exclusion criteria), biological variables (race/ethnicity, health status), ethical approvals (named IRBs), key resources (drug formulation), and statistical analysis (exact p-values, confidence intervals) reduce the overall rigor score.

The evaluation is based on the full text of the manuscript. The three independent reviewers largely agreed on the scientific premise, data/code availability, and reporting transparency, but diverged on study design, biological variables, ethical approvals, key resources, and statistical analysis. The synthesized judgments weigh the specific evidence provided by each reviewer. The statistics verification component found no tests to recompute (coverage note: limited to tests with test statistic + df or effect estimate + CI). The citation verification component was null. The reproducibility check found all 4 links live. The claim audit found no under-evidenced claims.

12 major claims checked against the paper's own evidence: all adequately supported.

Reporting

Eight Dimensions8 pass

The introduction thoroughly reviews the ANGPTL protein family, the differential regulation of LPL by ANGPTL3/8 versus ANGPTL3/4, genetic studies of ANGPTL3 and ANGPTL8 loss-of-function variants, and the limitations of existing therapies such as evinacumab, vupanorsen, and zodasiran. The rationale for developing a specific anti-ANGPTL3/8 antibody is logically built from these observations. The limitations of prior research (e.g., HDL-C lowering with ANGPTL3 inhibition, lesser LDL-C reduction with ASO/siRNA approaches) are explicitly acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise by extensively citing prior research on ANGPTL3/8 biology, genetic evidence, and earlier ANGPTL3-targeted agents, providing a logical rationale for targeting the ANGPTL3/8 complex specifically.

Evidence

direct quote[Introduction, paragraphs 1-3]

“The ability of ANGPTL3/8 to inhibit LPL activity has been shown to be suppressed by apolipoprotein (Apo)A-V, resulting in remnant cholesterol and triglyceride lowering.”

direct quote[Introduction, paragraph 3]

“Carriers of naturally occurring ANGPTL8 LOF variants, which reduce formation of the ANGPTL3/8 complex, show decreased triglyceride and LDL-C levels, increased HDL-C levels, and a reduced risk of CVD.”

direct quote[Discussion, paragraphs 5-6]

“A reason for this might be that ANGPTL3 ASO and siRNA compounds target ANGPTL3 production in the hepatocyte, whereas evinacumab and LY3475766 are monoclonal antibodies that act at the extracellular level.”

PASSReviewer 2· 95% conf

The paper establishes a strong scientific foundation, citing prior research on ANGPTL3/8 biology, genetic evidence, and preclinical studies to motivate the trial.

Evidence

direct quote[Introduction, paragraphs 1-3]

“Recent studies on how the ANGPTL protein family modulates LPL activity have identified the mechanisms by which LPL activity is controlled in a tissue-specific manner.”

direct quote[Introduction, paragraph 4]

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

direct quote[Discussion, paragraph 6]

“Evinacumab decreases the circulating HDL-C levels, probably because evinacumab also inhibits ANGPTL3 not bound to ANGPTL8...”

PASSReviewer 3· 95% conf

The study clearly establishes its scientific foundation with extensive prior literature and a logical rationale for targeting ANGPTL3/8.

Evidence

direct quote[Introduction, first paragraph]

“In recent years, agents inhibiting angiopoietin-like protein 3 (ANGPTL3) have been developed and have been shown to be effective in a wide spectrum of lipid disorders...”

direct quote[Introduction, paragraph 5]

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

direct quote[Discussion, paragraph 5]

“Evinacumab decreases the circulating HDL-C levels, probably because evinacumab also inhibits ANGPTL3 not bound to ANGPTL8...”

The study is described as 'randomized, double-blind' with participants allocated 6:2 to active or placebo within each cohort, which addresses randomization_method, randomization_unit, and blinding_levels adequately. Inclusion/exclusion criteria are explicitly listed (age 18-65, BMI 18.5-40, triglycerides 135-499 mg/dL, LDL-C ≥70 mg/dL). A pre-planned safety review before dose escalation was conducted. Power_analysis is not reported, which is acceptable for a phase 1 first-in-human study where the primary endpoint is safety. Blinding levels are adequately described as double-blind with placebo control, which is the field standard for this type of trial. Outlier handling is defined: 'Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.' Controls are the matched placebo group within each cohort. Independent_replication is not applicable as this is a first-in-human study.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study design is appropriate for a phase 1 trial: randomized, double-blind, placebo-controlled with single ascending doses. Key elements like randomization, blinding, and inclusion/exclusion criteria are well-reported, while power analysis is not applicable for a phase 1 safety/tolerability study.

Evidence

direct quote[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

direct quote[Methods, Trial design and oversight]

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

direct quote[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age, with a body mass index ≥18.5 to <40 kg m⁻², fasting triglyceride level 135–499 mg dl⁻¹, and fasting LDL-C level ≥70 mg dl⁻¹.”

PASSReviewer 2· 85% conf

The study design is described with adequate detail for a phase 1 trial, including randomization, blinding, and pre-specified criteria.

Evidence

direct quote[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

direct quote[Methods, Trial design and oversight]

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

direct quote[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age, with a body mass index ≥18.5 to <40 kg m−2, fasting triglyceride level 135–499 mg dl−1, and fasting LDL-C level ≥70 mg dl−1.”

direct quote[Methods, Statistical analysis]

“Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.”

direct quote[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

WARNReviewer 3· 85% conf

The study design is described but lacks a power analysis and detailed randomization method; inclusion/exclusion criteria are partially reported.

Evidence

direct quote[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

absence[Methods, Statistical analysis]

No power analysis or sample size calculation is reported.

direct quote[Methods, Study participants]

Sex is reported: 36 men and 12 women (75% male). Age, BMI, and key lipid parameters are reported in Table 1. As this is a human clinical study, species_strain_source and housing_conditions are not applicable. Demographics are reported in Table 1 including age, sex, and BMI. The study includes both sexes, so the 'sex_justified' criterion is not applicable. Age is reported as median (min, max) per group. Health status is addressed by the inclusion criteria ('overtly healthy').

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study adequately reports key biological variables for human participants: sex, age, BMI, lipid levels, and baseline health status are provided. Sex is reported, and while 75% of participants are male, the study includes both sexes so no separate single-sex justification is needed.

Evidence

direct quote[Abstract and Table 1]

“This study enrolled 48 adults (36 men, 12 women)”

direct quote[Table 1]

“Age (years) | 52 (20, 65) | 44 (25, 61) ... BMI (kg m⁻²) | 29.5 (25.1, 37.1)”

direct quote[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age”

PASSReviewer 2· 90% conf

Demographics and baseline characteristics of the human participants are well reported.

Evidence

direct quote[Table 1]

“Male sex (%) | 75 | 100 | 100 | 50 | 67 | 67”

direct quote[Table 1]

“Age (years) | 52 (20, 65) | 44 (25, 61) | 50 (31, 62) | 56 (30, 60) | 52 (33, 65) | 51 (31, 58)”

direct quote[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age...”

WARNReviewer 3· 80% conf

Sex and age are reported, but race/ethnicity is missing and health status is vague; the study is predominantly male.

Evidence

direct quote[Results, Baseline characteristics]

“A total of 75% of the participants were male, with a median age of 49 years, body mass index of 30.4 kg m−2.”

direct quote[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age...”

The trial was approved by the institutional review board or ethics committee at each site. Informed consent was obtained from participants. Compliance with the Declaration of Helsinki and ICH Good Clinical Practice is stated. A protocol number (J1T-MC-GZEA) is provided. The clinical trial is registered at ClinicalTrials.gov (NCT04052594). The ethics bodies are not named individually, which is common for multicenter trials but the statement is adequate as per the guidelines. Informed consent is explicitly stated. Regulatory compliance is named (Declaration of Helsinki, ICH-GCP).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementINADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper reports ethics committee approval, informed consent, and regulatory compliance adequately for a human clinical trial.

Evidence

direct quote[Methods, Trial design and oversight]

“The trial was approved by the institutional review board or ethics committee at each site.”

direct quote[Methods, Trial design and oversight]

“Participants provided written informed consent.”

direct quote[Methods, Trial design and oversight]

“The trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice, and applicable laws and regulations.”

PASSReviewer 2· 95% conf

Ethical approvals, consent, and regulatory compliance are clearly documented.

Evidence

direct quote[Methods, Trial design and oversight]

“The trial was approved by the institutional review board or ethics committee at each site.”

direct quote[Methods, Trial design and oversight]

“Participants provided written informed consent.”

direct quote[Methods, Trial design and oversight]

WARNReviewer 3· 90% conf

Ethics approval is stated but no named IRB or protocol number is provided; consent and regulatory compliance are adequately described.

Evidence

direct quote[Methods, Trial design and oversight]

“The trial was approved by the institutional review board or ethics committee at each site.”

direct quote[Methods, Trial design and oversight]

“Participants provided written informed consent. This study was registered at ClinicalTrials.gov (NCT04052594).”

The investigational product LY3475766 is named with its mechanism and preclinical development described. The placebo is identified (0.9% sodium chloride). No antibodies, cell lines, or wet-lab reagents are used in the clinical portion; these bench criteria are not applicable. Software tools are identified: Phoenix WinNonlin version 8.1 for noncompartmental pharmacokinetic analysis, and SAS version 9.4 for statistical analysis. Reagents_identified is scored against the investigational product, which is named with formulation (subcutaneous/intravenous) and dose, but no lot number or additional manufacturing details are provided — this is adequate for a phase 1 trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The investigational product (LY3475766) is identified, and protocol/supplementary materials are referenced for details. Software tools (Phoenix WinNonlin, SAS) are identified with versions. Bench reagents are not applicable as this is a clinical trial.

Evidence

direct quote[Abstract, Methods]

“LY3475766, a human monoclonal antibody that specifically blocks ANGPTL3/8-mediated inhibition of LPL activity.”

direct quote[Methods, Secondary endpoints; Methods, Statistical analysis]

“Pharmacokinetics were determined using noncompartmental methods (Phoenix WinNonlin version 8.1)”

direct quote[Methods, Trial design and oversight]

“participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants”

PASSReviewer 2· 85% conf

The investigational product (LY3475766) and key assays/software are adequately identified.

Evidence

direct quote[Introduction, paragraph 4; Methods, Trial design and oversight]

“LY3475766, a human monoclonal antibody that specifically blocks ANGPTL3/8-mediated inhibition of LPL activity.”

direct quote[Methods, Secondary endpoints; Statistical analysis]

“Pharmacokinetics were determined using noncompartmental methods (Phoenix WinNonlin version 8.1)”

direct quote[Methods, Statistical analysis]

“Data analysis was performed using SAS version 9.4.”

WARNReviewer 3· 85% conf

The investigational drug is identified but without formulation details; software tools are adequately identified.

Evidence

direct quote[Methods, Trial design and oversight]

“Participants were given LY3475766 in five single ascending dose cohorts: 10 mg intravenously, 30 mg intravenously, 100 mg subcutaneously, 300 mg subcutaneously and 600 mg subcutaneously.”

direct quote[Methods, Statistical analysis]

“Data analysis was performed using SAS version 9.4.”

Tests named: mixed model for repeated measures, Pearson correlation, power model for dose proportionality. Assumptions: normality assumption is indirectly addressed via log-transformation for skewed data, but explicit normality/equal variance tests for the mixed model are not reported; however, the model-based approach accommodates this. Exact p-values are not provided in the main text; instead, least-squares mean changes with standard errors are the primary reporting format. Pearson correlation p-values are reported to four decimal places. Effect sizes with confidence intervals are reported for the dose-proportionality analysis (Cmax ratio 6.9, 90% CI 2.9-16.3). Data presentation: Figures 1-5 show individual-group means with error bars (s.e.) over time, and n per group is stated. Mathematical plausibility: The reported percentages (e.g., 75% male, triglyceride reductions) are plausible given the sample sizes. No arithmetic errors were detected in the reviewed data.

Sub-criteria

tests namedADEQUATE

exact p valuesNOT REPORTED

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, the mixed model for repeated measures is described, and SAS version is reported. Exact p-values are not reported for direct comparisons but are acknowledged to be limited to four decimal places due to SAS. Confidence intervals are provided for some pharmacokinetic parameters. Data presentation includes least-squares means with standard errors and individual data points in figures.

Evidence

direct quote[Methods, Statistical analysis]

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter's change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

direct quote[Results, Figures 2-5]

“Figure 2 shows the maximum least-squares mean (s.e.) percent placebo-adjusted changes observed after treatment with LY3475766 for triglycerides (−69.9% (4.7%))”

direct quote[Methods, Statistical analysis]

“Due to computational limitations in SAS, P values are presented in the table to only four decimal places.”

direct quote[Results, Pharmacokinetics and target engagement]

“The ratio of the dose-normalized geometric mean Cmax of 600 mg versus 100 mg LY3475766 was 6.9 (90% confidence interval: 2.9–16.3).”

WARNReviewer 2· 90% conf

Statistical methods are named and analysis described, but exact p-values are generally not reported, and effect sizes with confidence intervals are limited for the primary safety endpoints.

Evidence

direct quote[Methods, Statistical analysis]

“A mixed model for repeated measures was used to evaluate treatment effect... The parameters were log-transformed prior to the analysis due to the skewness of the data.”

direct quote[Results, Lipid profile correlation analysis; Methods, Statistical analysis]

“P values are presented in the table to only four decimal places.”

direct quote[Results, Maximum percent change in lipid fractions]

“Maximum least-squares mean (s.e.) percent placebo-adjusted changes... triglycerides (−69.9% (4.7%))”

PASSReviewer 3· 80% conf

Statistical tests are named and software is identified, but exact p-values and confidence intervals for main outcomes are not reported.

Evidence

direct quote[Methods, Statistical analysis]

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter’s change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

direct quote[Results, Maximum percent change in lipid fractions]

“Figure shows the maximum least-squares mean (s.e.) percent placebo-adjusted changes observed after treatment with LY3475766 for triglycerides (−69.9% (4.7%))...”

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

A detailed data availability statement is provided, specifying controlled access via Vivli for individual participant data with explicit terms. Code sharing is not applicable for a clinical trial using standard software. No accession numbers for public repositories are applicable for identifiable clinical data.

Evidence

direct quote[Data availability section]

“Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, except for pharmacokinetic or genetic data. Data are available by request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later.”

direct quote[Data availability section]

“access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement and will be provided as soon as reasonably possible.”

direct quote[Data availability section]

“For details on submitting a request, see the instructions provided at www.vivli.org.”

PASSReviewer 2· 90% conf

A detailed data availability statement is provided, specifying managed access via Vivli for individual participant data.

Evidence

direct quote[Data availability section]

“Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization... Data are available by request 6 months after the indication studied has been approved... access is provided after a proposal has been approved by an independent review committee... For details on submitting a request, see the instructions provided at www.vivli.org.”

direct quote[Methods, Trial design and oversight, and Statistical analysis]

“The protocol for the study J1T-MC-GZEA is provided in the Supplementary Information. The statistical analysis plan for the study J1T-MC-GZEA is provided in the Supplementary Information.”

PASSReviewer 3· 95% conf

A detailed data availability statement is provided, specifying managed access via Vivli; no custom code or public repository deposit is applicable.

Evidence

direct quote[Data availability section]

Methods completeness: The protocol and SAP are provided in the supplementary materials, and methods sections are detailed enough for replication. Trial registration: NCT04052594 is provided in the abstract and methods. Reporting guideline: A 'Reporting Summary' is linked, suggesting adherence to a guideline, but it is not explicitly named (e.g., CONSORT). All_outcomes_reported: All pre-specified outcomes (safety, PK, PD) are reported, with negative results (e.g., modest/no changes for ApoA-I, ApoA-II) included. Limitations_discussed: The discussion mentions limitations including the single-dose design, the need for multiple-ascending-dose studies, the impact of COVID-19 on enrollment, and the lack of cardiovascular outcome data. Conclusions_proportional: The conclusions are appropriately cautious (e.g., 'the effects on cardiovascular risk remain to be established'). Funding_coi: Funding from Eli Lilly is stated, and detailed competing interests are provided for all authors.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent overall: it is a registered clinical trial, methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. Reporting checklists (CONSORT/ARRIVE) are not explicitly mentioned, but a 'Reporting Summary' is linked.

Evidence

direct quote[Abstract, Methods]

“ClinicalTrials.gov registration: NCT04052594”

direct quote[Discussion, paragraph 10]

“Further studies are needed to confirm these findings, with the next steps likely to include a multiple ascending dose study to determine the optimal dosing of LY3475766 required to achieve maximum reductions...”

direct quote[Discussion, final paragraph]

“These results warrant further human trials to assess the safety and efficacy of LY3475766 for the treatment of lipid disorders and for the prevention and/or treatment of atherosclerotic CVD, acute pancreatitis, or other morbidities.”

PASSReviewer 2· 90% conf

The paper is well-structured, reports a trial registration, discusses limitations, and conclusions are proportional to the evidence.

Evidence

direct quote[Abstract; Methods]

“ClinicalTrials.gov registration: NCT04052594”

direct quote[Discussion, final paragraphs]

“Further studies are needed to confirm these findings, with the next steps likely to include a multiple ascending dose study...”

direct quote[Abstract; Discussion]

“LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established.”

PASSReviewer 3· 85% conf

The trial is registered, outcomes are reported, limitations are discussed, and conclusions are proportional; methods are mostly complete but lack some details.

Evidence

direct quote[Abstract and Methods]

“ClinicalTrials.gov registration: NCT04052594.”

direct quote[Discussion, final paragraph]

“These results warrant further human trials to assess the safety and efficacy of LY3475766 for the treatment of lipid disorders.”

paraphrase[Methods, Study participants]

“Exclusion criteria are not explicitly listed; only 'overtly healthy' is stated.”

7 copyedit issues flagged: mostly other, clarity, typo.

Reproducibility

4 data/code links checked; 4 live.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Adcurare Rigor Action ItemsFinal pass before journal submission

The manuscript is ready for submission after addressing the prioritized action items. The most consequential gaps are the missing randomization method, incomplete blinding details, and lack of exact p-values/confidence intervals for primary endpoints. These are reporting gaps that can be fixed without additional data collection.

1.
HIGHreporting
Specify the randomization method (e.g., computer-generated random number sequence) in the 'Trial design and oversight' Methods section.
The current statement is inadequate for reproducibility; a method must be named.
2.
HIGHreporting
Detail the blinding implementation (who was blinded: participants, investigators, outcome assessors) in the 'Trial design and oversight' section.
The current 'double-blind' statement is insufficient; the level of blinding must be specified.
3.
HIGHreporting
List all exclusion criteria explicitly in the 'Study participants' Methods section.
Only inclusion criteria are currently provided; exclusion criteria are essential for reproducibility.
4.
HIGHstatistics
Report exact p-values (e.g., from the mixed model for repeated measures) for the primary pharmacodynamic endpoints in the Results section or in a table.
Exact p-values are a standard reporting requirement; the current reporting of only least-squares means and SE is inadequate.
5.
HIGHstatistics
Include 95% confidence intervals for the key effect sizes (e.g., percent changes in lipids) in the Results section or figures.
Confidence intervals provide essential information about precision; currently only one CI is reported.
6.
HIGHethics
Name the specific institutional review boards (IRBs) or ethics committees that approved the study protocol in the 'Trial design and oversight' section.
The current generic statement is inadequate; named bodies are required for transparency.
7.
HIGHreporting
Report race/ethnicity of participants in the baseline characteristics table (Table 1).
Race/ethnicity is an important demographic variable for generalizability and is currently missing.
8.
HIGHreporting
Provide a more specific health status assessment for participants beyond 'overtly healthy' in the 'Study participants' section.
The current description is vague; specific criteria or a reference to a standard assessment would improve clarity.
9.
HIGHreporting
Provide the formulation (e.g., concentration, buffer) of the investigational drug LY3475766 in the Methods section.
Formulation details are a key resource identifier and are currently missing.
10.
MEDIUMstatistics
State whether normality and homoscedasticity assumptions were checked for the mixed model, even if log-transformation was used, in the 'Statistical analysis' section.
Assumption verification is a standard reporting requirement; the current statement is inadequate.
11.
MEDIUMreporting
Explicitly mention the reporting guideline followed (e.g., CONSORT for phase 1 trials) in the Methods or Reporting Summary note.
The current reference to a 'Reporting Summary' is vague; naming the guideline improves transparency.
12.
MEDIUMcopyedit
Correct the typo 'ANPTL3/8' to 'ANGPTL3/8' in the Abstract.
Inconsistent abbreviation could cause confusion.
13.
MEDIUMcopyedit
Remove the space after the minus sign in percentage values (e.g., '- 29.5%' to '-29.5%') in the Results section.
Inconsistent spacing in percentage values is a formatting error.
14.
MEDIUMcopyedit
Clarify the 'NA' entry for ApoA-I in the 600 mg group in Table 1 (e.g., state 'not available' or provide the value).
Missing data point in the table is unclear to readers.
15.
LOWcopyedit
Consider adding the magnitude of the decreases for the 'slight decreases in global cholesterol efflux' in the Results section.
The adjective 'slight' is vague; a quantitative range would be more precise.

Full text (49,677 chars)Analyzed: Jul 6, 2026

Read alongside